Fairmount Funds Management as of June 30, 2025
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 17 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 11.5 | $89M | 2.0M | 43.43 | |
| Axsome Therapeutics (AXSM) | 11.0 | $85M | 815k | 104.39 | |
| Enliven Therapeutics (ELVN) | 9.6 | $75M | 3.7M | 20.06 | |
| Scholar Rock Hldg Corp (SRRK) | 8.4 | $65M | 1.8M | 35.42 | |
| Spyre Therapeutics Com New (SYRE) | 7.8 | $60M | 4.0M | 14.97 | |
| Nuvalent Inc-a (NUVL) | 7.2 | $56M | 728k | 76.30 | |
| Dianthus Therapeutics (DNTH) | 6.5 | $50M | 2.7M | 18.63 | |
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 6.4 | $49M | 1.8M | 27.67 | |
| Miragen Therapeutics (VRDN) | 6.3 | $48M | 3.5M | 13.98 | |
| Cogent Biosciences (COGT) | 5.8 | $45M | 6.2M | 7.18 | |
| Oruka Therapeutics (ORKA) | 4.9 | $38M | 3.4M | 11.21 | |
| Jade Biosciences Com New (JBIO) | 4.2 | $32M | 3.2M | 9.99 | |
| Crescent Biopharma (CBIO) | 2.9 | $22M | 1.4M | 16.14 | |
| Astria Therapeutics (ATXS) | 2.5 | $19M | 3.6M | 5.36 | |
| Zenas Biopharma (ZBIO) | 2.4 | $18M | 1.9M | 9.69 | |
| Inhibikase Therapeutics Com New (IKT) | 1.5 | $12M | 6.1M | 1.95 | |
| Cytomx Therapeutics (CTMX) | 1.1 | $8.8M | 3.9M | 2.27 |
